Dexamethasone exposure in normal‐weight and obese hospitalized COVID‐19 patients: An observational exploratory trial

During the latest pandemic, the RECOVERY study showed the benefits of dexamethasone (DEX) use in COVID‐19 patients. Obesity has been proven to be an independent risk factor for severe forms of infection, but little information is available in the literature regarding DEX dose adjustment according to...

Descripción completa

Detalles Bibliográficos
Autores principales: Abouir, Kenza, Gosselin, Pauline, Guerrier, Stéphane, Daali, Youssef, Desmeules, Jules, Grosgurin, Olivier, Reny, Jean‐Luc, Samer, Caroline, Calmy, Alexandra, Ing Lorenzini, Kuntheavy Roseline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9283739/
https://www.ncbi.nlm.nih.gov/pubmed/35706350
http://dx.doi.org/10.1111/cts.13297

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9283739/
https://www.ncbi.nlm.nih.gov/pubmed/35706350
http://dx.doi.org/10.1111/cts.13297

Ejemplares similares